ARCH Venture Partners Joins Investor Team New Financing Will Further Advance the Beta-Thalassemia, Sickle Cell Anemia and ALD Clinical Programs While Accelerating the Product Platform …
bluebird bio Appoints World Leading Experts to Inaugural Scientific Advisory Board
bluebird bio Appoints World Leading Experts to Inaugural Scientific Advisory Board CAMBRIDGE, Mass., March 21, 2011 – bluebird bio, an emerging leader in the development of innovative gene therapies …
bluebird bio Awarded up to $4.2 Million from the French Muscular Dystrophy Association for Continued Development of Gene Therapy for Beta-Thalassemia and Sickle Cell Anemia
CAMBRIDGE, Mass., March 16, 2011 – bluebird bio, an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced that it has entered into an agreement …